Antiparasitic medication

PreclinicalSmall molecule

UUniversity of North Carolina, Chapel Hill

Antiparasitic medication is one of 6 small molecule programs targeting Parasitic Infection. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Parasitic InfectionActive, not recruiting

Parasitic InfectionPreclinical

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Parasitic Infection

#DrugCompanyPhaseTrials

Antabuse

Albendazole.

1 3

Iron Supplement

TThe University of Texas Health Science Center, Houston

Approved

1 4

Flagyl

DDePuy Orthopaedics

Preclinical

2 5

Echinacea Extract

AAl-Azhar University

Preclinical

1 6

Antiparasitic medication

UUniversity of North Carolina, Chapel Hill

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Parasitic Infection1 trial

HIV And Parasitic Infection (HAPI) Study

Completed·UUniversity of North Carolina, Chapel Hill·N/A·NCT05323396·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Antiparasitic medication. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Antiparasitic medication compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Antiparasitic medication. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of North Carolina, Chapel Hill company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of North Carolina, Chapel Hill

Antiparasitic medication

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Parasitic Infection1 trial

References

Drug Info

Quick Facts

Related News